Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes
necessary for cancer cell growth. Drugs used in chemotherapy such as
17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from
dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill
more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of
17-N-allylamino-17-demethoxygeldanamycin when given together with imatinib mesylate in
treating patients with chronic myelogenous leukemia.